Teacher Retirement System of Texas Has $91,000 Position in Sana Biotechnology, Inc. (NASDAQ:SANA)

Teacher Retirement System of Texas lowered its position in Sana Biotechnology, Inc. (NASDAQ:SANAFree Report) by 9.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 22,226 shares of the company’s stock after selling 2,253 shares during the quarter. Teacher Retirement System of Texas’ holdings in Sana Biotechnology were worth $91,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. E Fund Management Co. Ltd. lifted its stake in shares of Sana Biotechnology by 40.0% during the 4th quarter. E Fund Management Co. Ltd. now owns 23,361 shares of the company’s stock worth $95,000 after buying an additional 6,673 shares during the last quarter. Swiss National Bank lifted its stake in shares of Sana Biotechnology by 3.5% during the 4th quarter. Swiss National Bank now owns 194,100 shares of the company’s stock worth $792,000 after buying an additional 6,600 shares during the last quarter. Victory Capital Management Inc. acquired a new stake in shares of Sana Biotechnology during the 4th quarter worth about $54,000. Simplex Trading LLC lifted its stake in shares of Sana Biotechnology by 31.3% during the 4th quarter. Simplex Trading LLC now owns 18,080 shares of the company’s stock worth $73,000 after buying an additional 4,313 shares during the last quarter. Finally, New York State Common Retirement Fund lifted its stake in shares of Sana Biotechnology by 5.4% during the 4th quarter. New York State Common Retirement Fund now owns 40,564 shares of the company’s stock worth $166,000 after buying an additional 2,082 shares during the last quarter. Institutional investors and hedge funds own 88.23% of the company’s stock.

Sana Biotechnology Stock Performance

NASDAQ:SANA opened at $7.61 on Friday. Sana Biotechnology, Inc. has a 52 week low of $2.74 and a 52 week high of $12.00. The firm has a market cap of $1.69 billion, a price-to-earnings ratio of -4.97 and a beta of 1.62. The firm’s 50-day simple moving average is $8.79 and its 200 day simple moving average is $7.01.

Sana Biotechnology (NASDAQ:SANAGet Free Report) last released its quarterly earnings results on Wednesday, May 8th. The company reported ($0.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.02). Sell-side analysts anticipate that Sana Biotechnology, Inc. will post -1.15 EPS for the current year.

Analyst Ratings Changes

SANA has been the subject of a number of research reports. HC Wainwright restated a “buy” rating and set a $12.00 target price on shares of Sana Biotechnology in a research note on Thursday, May 9th. JMP Securities raised their target price on shares of Sana Biotechnology from $8.00 to $15.00 and gave the stock a “market outperform” rating in a research note on Friday, March 1st.

Check Out Our Latest Stock Analysis on Sana Biotechnology

Sana Biotechnology Profile

(Free Report)

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.

See Also

Want to see what other hedge funds are holding SANA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sana Biotechnology, Inc. (NASDAQ:SANAFree Report).

Institutional Ownership by Quarter for Sana Biotechnology (NASDAQ:SANA)

Receive News & Ratings for Sana Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sana Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.